Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing

K. A. Birdwell, B. Decker, J. M. Barbarino, J. F. Peterson, C. M. Stein, W. Sadee, D. Wang, A. A. Vinks, Y. He, J. J. Swen, J. S. Leeder, R. H.N. Van Schaik, K. E. Thummel, T. E. Klein, K. E. Caudle, I. A.M. MacPhee

Research output: Contribution to journalArticle

186 Scopus citations

Abstract

Tacrolimus is the mainstay immunosuppressant drug used after solid organ and hematopoietic stem cell transplantation. Individuals who express CYP3A5 (extensive and intermediate metabolizers) generally have decreased doseâ djusted trough concentrations of tacrolimus as compared with those who are CYP3A5 nonexpressers (poor metabolizers), possibly delaying achievement of target blood concentrations. We summarize evidence from the published literature supporting this association and provide dosing recommendations for tacrolimus based on CYP3A5 genotype when known (updates at www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)19-24
Number of pages6
JournalClinical Pharmacology and Therapeutics
Volume98
Issue number1
DOIs
StatePublished - Jul 1 2015

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing'. Together they form a unique fingerprint.

  • Cite this

    Birdwell, K. A., Decker, B., Barbarino, J. M., Peterson, J. F., Stein, C. M., Sadee, W., Wang, D., Vinks, A. A., He, Y., Swen, J. J., Leeder, J. S., Van Schaik, R. H. N., Thummel, K. E., Klein, T. E., Caudle, K. E., & MacPhee, I. A. M. (2015). Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing. Clinical Pharmacology and Therapeutics, 98(1), 19-24. https://doi.org/10.1002/cpt.113